David Haas, MD

Dr. Haas’ research is focused on HIV clinical trials and human pharmacogenomic research relevant to HIV infection and its therapy. He established and has led the AIDS Clinical Trials Group (ACTG) Clinical Research Site at Vanderbilt since its inception. He previously chaired the Pharmacology Committee for the AIDS Clinical Trials Group (ACTG), led the ACTG’s pharmacogenomics program since 2000, and presently serve on the ACTG Executive Committee. His work led to the observation that a frequent CYP2B6 polymorphism predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent and may help predict CNS side effects and virologic response. He is highly engaged in collaborative, multidisciplinary research with an emphasis on the importance of human genomics for antiretroviral disposition, efficacy, and toxicity.